Johnson & Johnson is an investment fund managing more than $401 billion ran by Marc Larkins. There are currently 20 companies in Mr. Larkins’s portfolio. The largest investments include Protagonist Therapeutics Inc and Rapport Therapeutics, Inc., together worth $143 billion.
As of 2nd August 2024, Johnson & Johnson’s top holding is 2,449,183 shares of Protagonist Therapeutics Inc currently worth over $84.9 billion and making up 21.2% of the portfolio value.
Relative to the number of outstanding shares of Protagonist Therapeutics Inc, Johnson & Johnson owns more than approximately 0.1% of the company.
In addition, the fund holds 2,498,051 shares of Rapport Therapeutics, Inc. worth $58.1 billion.
The third-largest holding is Cvrx, Inc. worth $49.2 billion and the next is Legend Biotech Corp worth $36.1 billion, with 814,586 shares owned.
Currently, Johnson & Johnson's portfolio is worth at least $401 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Johnson & Johnson office and employees reside in New Brunswick, New Jersey. According to the last 13-F report filed with the SEC, Marc Larkins serves as the Secretary at Johnson & Johnson.
In the most recent 13F filing, Johnson & Johnson revealed that it had opened a new position in
Rapport Therapeutics, Inc. and bought 2,498,051 shares worth $58.1 billion.
On the other hand, there are companies that Johnson & Johnson is getting rid of from its portfolio.
Johnson & Johnson closed its position in Kenvue Inc. on 9th August 2024.
It sold the previously owned 182,329,550 shares for $3.91 trillion.
The two most similar investment funds to Johnson & Johnson are Sierra Summit Advisors and Icon Advisers Inc/co. They manage $401 billion and $401 billion respectively.
Johnson & Johnson’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 52.9% of
the total portfolio value.
The fund focuses on investments in the United States as
45.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
5% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $1.46 billion.
These positions were updated on August 9th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Kenvue Inc. |
Closed
182,329,550
|
$3,912,792,143,000 | |
| Protagonist Therapeutics Inc |
No change
2,449,183
|
$84,864,191,000 | 21.18% |
| Fusion Pharmaceuticals Inc. |
Closed
3,670,516
|
$78,255,401,000 | |
| Rapport Therapeutics, Inc. |
Opened
2,498,051
|
$58,104,666,000 | 14.50% |
| Shockwave Medical Inc. |
Closed
166,812
|
$54,318,992,000 | |
| Cvrx, Inc. |
No change
4,103,430
|
$49,200,126,000 | 12.28% |
| Legend Biotech Corp |
No change
814,586
|
$36,078,014,000 | 9.00% |
| Contineum Therapeutics Inc. |
Opened
1,979,173
|
$34,853,237,000 | 8.70% |
| Nanobiotix S.A. |
No change
5,623,816
|
$28,119,080,000 | 7.02% |
| MeiraGTx Holdings plc |
No change
6,641,064
|
$27,958,879,000 | 6.98% |
| Procept Biorobotics Corporation |
No change
357,939
|
$21,866,494,000 | 5.46% |
| Neumora Therapeutics, Inc. |
No change
1,849,445
|
$18,180,044,000 | 4.54% |
| Xencor Inc |
No change
748,062
|
$14,160,814,000 | 3.53% |
| Fate Therapeutics Inc |
No change
3,379,064
|
$11,083,330,000 | 2.77% |
| Arrowhead Pharmaceuticals Inc. |
No change
247,598
|
$6,435,072,000 | 1.61% |
| Rallybio Corporation |
Opened
3,636,363
|
$4,872,726,000 | 1.22% |
| Nano-X Imaging Ltd. |
No change
158,852
|
$1,165,974,000 | 0.29% |
| Vor Biopharma, Inc. |
No change
1,074,658
|
$1,074,658,000 | 0.27% |
| Aldeyra Therapeutics Inc |
No change
299,669
|
$991,904,000 | 0.25% |
| BiomX Inc |
No change
1,923,201
|
$646,388,000 | 0.16% |
| Standard BioTools Inc |
No change
311,967
|
$552,182,000 | 0.14% |
| Adicet Bio, Inc. |
No change
364,472
|
$441,011,000 | 0.11% |
| Clearside Biomedical Inc |
Closed
169,629
|
$259,532,000 | |
| TRACON Pharmaceuticals Inc |
Closed
84,003
|
$36,104,000 | |
| Senseonics Holdings Inc |
No change
54,621
|
$21,794,000 | 0.01% |
| No transactions found | |||
| Showing first 500 out of 25 holdings | |||